Genetic Medicine Institute
Rare diseases are among the most serious of all illnesses and impact millions of patients worldwide. Pfizer’s focus on rare diseases builds on more than a decade of experience and a global portfolio of 22 medicines approved worldwide that treat rare diseases.
Pfizer developed the new Genetic Medicine Institute in central London with a core focus on evaluating the viability of producing effective, clinical grade gene therapy viruses at pace and scale.
Its team of research scientists actively examines the infrastructure behind gene therapy development and seeks to develop certain gene therapy pipeline projects in Pfizer’s portfolio.
As a specialist centre that welcomes academics, pharmaceutical professionals and leading scientists, the task for Greenspace was to create the Genetic Medicine Institute brand identity along with detailed information and environmental graphics that help Pfizer’s visitors and guests to orientate the highly complex journey of Rare Disease medicine development.
“I am excited to join Pfizer’s Genetic Medicine Institute full-time in order to generate potential new medicines in this important area.”
Professor Michael Linden — Pfizer Genetic Medicine Institute — London